Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity

Vaccine

Volumn 34, Issue 4, 2016, Pages 458-465

  Eichelberger, Maryna C ^a   Couzens, Laura ^a   Gao, Yonghong ^b   Levine, Min ^c   Katz, Jacqueline ^c   Wagner, Ralf ^d   Thompson, Catherine I ^e   Höschler, Katja ^e   Laurie, Karen ^f   Bai, Tian ^g   Engelhardt, Othmar G ^h   Woodi, John ⁱ  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Department of Health and Human Services   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d PAUL EHRLICH INSTITUT   (Germany)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f WHO Collaborating Centre for Reference and Research   (Australia)

^g NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION   (China)

^h NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

ⁱ Formerly National Institute for Biological Standards and Control   (United Kingdom)

Author keywords

Assay; CONSISE; ELLA; Influenza; Neuraminidase; Variability

Indexed keywords

ANTIGEN; INFLUENZA VACCINE; SIALIDASE; INACTIVATED VACCINE; NA PROTEIN, INFLUENZA A VIRUS; VIRAL PROTEIN; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CROSS REACTION; ENZYME INHIBITION ASSAY; ENZYME LINKED LECTIN ASSAY; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; SEROLOGY; STANDARDIZATION; ANIMAL; BLOOD; BOVINE; CLASSIFICATION; ENZYME IMMUNOASSAY; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); REPRODUCIBILITY; SERODIAGNOSIS; STANDARDS;

ANIMALS; ANTIBODIES, VIRAL; CATTLE; CROSS REACTIONS; HUMANS; IMMUNOENZYME TECHNIQUES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; NEURAMINIDASE; NEUTRALIZATION TESTS; REPRODUCIBILITY OF RESULTS; VACCINES, INACTIVATED; VIRAL PROTEINS;

EID: 84952950736     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.022     Document Type: Article

References (18)

1. Lambre C.R., Terzidis H., Greffard A., Webster R.G. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990, 135:49-57.
2. Couzens L., Gao J., Westgeest K., Sandbulte M., Lugovtsev V., Fouchier R., et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Methods 2014, 210:7-14.
3. Westgeest K.B., Bestebroer T.M., Spronken M.I., Gao J., Couzens L., Osterhaus A.D., et al. Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses. J Virol Methods 2015, 217:55-63.
4. Laver W.G., Kilbourne E.D. Identification in a recombinant influenza virus of structural proteins derived from both parents. Virology 1966, 30:493-501.
5. Aminoff D. The determination of free sialic acid in the presence of the bound compound. Virology 1959, 7:355-357.
6. Lotan R., Skutelsky E., Danon D., Sharon N. The purification, composition, and specificity of the anti-T lectin from peanut (Arachis hypogaea). J Biol Chem 1975, 250:8518-8523.
7. Cate T.R., Rayford Y., Nino D., Winokur P., Brady R., Belshe R., et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28:2076-2079.
8. Couch R.B., Atmar R.L., Franco L.M., Quarles J.M., Wells J., Arden N., et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013, 207:974-981.
9. Fries L.F., Smith G.E., Glenn G.M. A recombinant virus-like particle influenza A (H7N9) vaccine. N Engl J Med 2013, 369:2564-2566.
10. Couch R.B., Atmar R.L., Keitel W.A., Quarles J.M., Wells J., Arden N., et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 2012, 31:190-195.
11. Hassantoufighi A., Zhang H., Sandbulte M., Gao J., Manischewitz J., King L., et al. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010, 28:790-797.
12. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972, 286:1329-1332.
13. Laurie K.L., Engelhardt O.G., Wood J., Heath A., Katz J.M., Peiris M., et al. International laboratory comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses by CONSISE. Clin Vaccine Immunol 2015, 22:957-964.
14. Barr I.G., McCauley J., Cox N., Daniels R., Engelhardt O.G., Fukuda K., et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season. Vaccine 2010, 28:1156-1167.
15. Sandbulte M.R., Gao J., Straight T.M., Eichelberger M.C. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses 2009, 3:233-240.
16. Stephenson I., Heath A., Major D., Newman R.W., Hoschler K., Junzi W., et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009, 15:1252-1259.
17. Wood J.M., Major D., Heath A., Newman R.W., Hoschler K., Stephenson I., et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine 2012, 30:210-217.
18. Fritz R., Sabarth N., Kiermayr S., Hohenadl C., Howard M.K., Ilk R., et al. A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 2012, 205:28-34.